European Union Grants Conditional Approval For Gilead’s Remdesivir

By Ariel Cohen / July 6, 2020 at 3:05 PM
The European Commission will let Gilead sell remdesivir to its 27-country bloc while scientists continue to study the antiviral as a COVID-19 treatment, making it the first drug conditionally approved to treat the virus in the European Union. “This is an important step forward in our efforts against COVID-19. We will leave no stone unturned to provide our citizens with access to safe and effective therapies,” Stella Kyriakides, EU commissioner for health and food safety, tweeted upon hearing the news...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.